Erin Rose is a seasoned strategic Talent Acquisition leader at Novo Nordisk, bringing over 21 years of extensive experience in the pharmaceutical industry to her role as Associate Director. In her current position, Erin plays a pivotal role as a member of the North American...
Erin Rose is a seasoned strategic Talent Acquisition leader at Novo Nordisk, bringing over 21 years of extensive experience in the pharmaceutical industry to her role as Associate Director. In her current position, Erin plays a pivotal role as a member of the North American Talent Acquisition leadership team, where she is instrumental in shaping and executing the talent acquisition strategy across diverse business areas. Her leadership extends to managing a dynamic team of recruiters who specialize in Clinical, Medical, Regulatory, Research & Early Development, and Enabling Functions, ensuring that Novo Nordisk attracts top-tier talent to drive innovation and excellence in the pharmaceutical landscape.
Erin’s expertise lies not only in recruitment but also in understanding the intricacies of the pharmaceutical sector, particularly in areas such as oncology and cardiology. She adeptly navigates the complexities of clinical development and medical writing, leveraging her skills in compensation and offer development to craft compelling value propositions for candidates. Erin is well-versed in utilizing advanced recruitment technologies, including Taleo, to streamline the hiring process and enhance candidate experience.
Key projects under Erin’s leadership have included the implementation of strategic initiatives aimed at improving diversity and inclusion within the workforce, aligning with Novo Nordisk's commitment to fostering a culture of innovation and collaboration. Her strategic vision and ability to build strong relationships across various affiliates have positioned her as a trusted partner in driving organizational success. With a focus on continuous improvement and a passion for talent development, Erin Rose is dedicated to ensuring that Novo Nordisk remains at the forefront of the pharmaceutical industry through its most valuable asset—its people.
